Literature DB >> 2952599

Platelets as effectors in immune and hypersensitivity reactions.

A Capron, M Joseph, J C Ameisen, M Capron, V Pancré, C Auriault.   

Abstract

IgE receptors have been recently characterized on human blood platelets. These receptors share common properties within the Fc epsilon R2 previously described on macrophages and eosinophils with a Ka of 3 X 10(7) M-1 and a mean number of 600-1,000 binding sites for IgE per platelet. The production of an anti-Fc epsilon R2 monoclonal antibody has allowed the identification on platelet membrane preparations of two major bands of 43-45 and 31 kD. In parasitic infections (schistosomiasis, filariasis) IgE-dependent killing by platelets has been demonstrated. In allergic asthma and in Hymenoptera venom sensitivity patients, IgE-dependent activation of platelets expressed by the release of cytocidal mediators and oxidative burst can be specifically triggered by the corresponding allergen. In aspirin-sensitive asthma, a direct, non-IgE-dependent platelet activation by nonsteroidal anti-inflammatory drugs has been demonstrated. The platelet abnormality apparently involved a defect of the prostaglandin H2 binding to its specific receptor and a possible imbalance in the regulatory functions of the lipoxygenase metabolites. Platelet effector functions have been recently shown to be regulated by T cell factors. A novel suppressive lymphokine (PASL) produced by OKT8 T cell subset inhibits platelet activation and killing whereas IFN-gamma has been identified among T cell factors produced by OKT4+ cells able to trigger platelet activation. These observations open original perspectives into the pathogenesis, the diagnosis and the prevention of allergic and pseudoallergic disorders, and they provide support to the concept of a role for platelets in various immune and hypersensitivity reactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952599     DOI: 10.1159/000234214

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  8 in total

Review 1.  Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE.

Authors:  C G Magnusson; S G Johansson
Journal:  Clin Rev Allergy       Date:  1989

2.  The abnormal in vitro response to aspirin of platelets from aspirin-sensitive asthmatics is inhibited after inhalation of nedocromil sodium but not of sodium cromoglycate.

Authors:  C H Marquette; M Joseph; A B Tonnel; H Vorng; P Lassalle; A Tsicopoulos; A Capron
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

3.  Antigen induces leucopenia in non-immunised guinea-pigs injected with platelets from actively sensitized animals.

Authors:  M Pretolani; J Randon; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

Review 4.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 5.  The pathophysiology of anaphylaxis.

Authors:  Laurent L Reber; Joseph D Hernandez; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

6.  Comparative analysis of biological activities of Der p I-derived peptides on Fc epsilon receptor-bearing cells from Dermatophagoides pteronyssinus-sensitive patients.

Authors:  P Jeannin; J Pestel; M Bossus; P Lassalle; A Tartar; A B Tonnel
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Accumulation of platelets in the lung and liver and their degranulation following antigen-challenge in sensitized mice.

Authors:  Atsushi Yoshida; Mami Ohba; Xia Wu; Takashi Sasano; Masanori Nakamura; Yasuo Endo
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 8.  Expression, regulation and function of human Fc epsilon RII (CD23) antigen.

Authors:  M Sarfati; S Fournier; C Y Wu; G Delespesse
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.